Introduction: Tuberculosis (TB) is a chronic communicable disease caused by Mycobacterium tuberculosis (MTB). M. tuberculosis is a slow- growing bacterium, resistant to most conventional antimicrobial agents partly due to its impermeable cell wall. It may persist in a dormant or latent form, unsusceptible to agents targeting growing bacteria. The Gen Xpert MTB/RIF is an automated molecular test which detects DNA sequences specific for MTB and RIF resistance by polymerase chain reaction with fully integrated sample processing in patients suspected of drug sensitive or multidrug resistant pulmonary tuberculosis. Objective: to determine Rifampicin Mono-Resistance Mycobacterium tuberculosis among patient attending atYirgalem Hospital from August-December, 2014.Method:A cross sectional study was conducted on Rifampicin Mono-Resistance in Mycobacterium tuberculosis among patient attending at Yirgalem Hospital from August-December, 2014,Yirgalem, Ethiopia. Result: A total of 236 participants were included under this study. Among these, males (57.6%) are slightly dominating female. Concerning to treatment history, 177 (75.0%) are new and the rest 59 (25.0%) retreated. Fifty eight (24.6%) of the total subjects were suspected for MDR tuberculosis. Twenty two (9.3%) of the subjects were smear positive. The highest positive finding of rifampcin susceptible Mycobacterium tuberculosis bacilli observed within age group of 16-30.The overall prevalence of pulmonary tuberculosis was 16.5%. From this prevalence, 3.4% was shared by Rifampcin mono-resistant Tuberculosis. Conclusion: Based on our study finding, The overall prevalence of pulmonary tuberculosis was 16.5%. From these, 3.4% was account for Rifampicin Mono-Resistance Mycobacterium tuberculosis among study subject. Most of the affected study subjects were productive age group. Therefore, we recommend that there should be enhanced efforts in detection of MDR tuberculosis in study area to control dissemination of the disease among the community.
| Published in | Clinical Medicine Research (Volume 4, Issue 3) |
| DOI | 10.11648/j.cmr.20150403.13 |
| Page(s) | 75-78 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Tuberculosis, Rifampcin, Yirgalem Hospital
| [1] | Murray, C.J. (2000). A Critical Examination of Summary Measures of Population Health. Buletin. WHO 78, 981-994. |
| [2] | Jean D. Wilson et al Harrison’s Principles of Internal Medicine. Thomas A. Daniel. Tuberculosis 12th Ed. 1991. |
| [3] | World Health Organisation (WHO): Global tuberculosis control: Surveillance, planning and financing. WHO report. WHO/HTM TB/362. Genev2006. |
| [4] | World Health Organization. WHO Report 2005. Global tuberculosis control: surveillance, planning and financing. Geneva, Switzerland: WHO, 2005. |
| [5] | World Health Organisation (WHO): Globaltuberculosis control: Surveillance, planning and financing. WHO report. WHO/HTM/TB/2008.393. Geneva 2008. |
| [6] | Ministry of Health of Ethiopia (MOH): Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme Manual. Addis Ababa: MOH4th edition. 2008. |
| [7] | World Health Organization. Assessing tuberculosis prevalence through population-basedsurveys. Geneva: World Health Organization; 2007 |
| [8] | Southern Ethiopia Regional State Health Bureau: The Health Sector Development Plan (2000-2004). Awassa, RHB; 2001. |
| [9] | Lindtjørn B, Madebo T: The outcome of tuberculosis treatment at a rural hospital in Southern Ethiopia. Tropical Doctor 2001, 31:132-135. |
| [10] | Yassin MA, Takele L, Gebresenbet S, Girma E, Lera M, Lendebo E, Cuevas LE: HIV and Tuberculosis Coinfection in the SouthernRegion of Ethiopia: A Prospective Epidemiological Study. Scand J Infect Dis 2004, 36:670-673. |
| [11] | Bello LA, Shittu MO, Shittu BT, Oluremi AS, Akinnuroju ON, Adekola SA. Rifampicin-monoresistant Mycobacterium tuberculosis among the patients visiting chest clinic, state specialist hospital, Akure, Nigeria. Int J Res Med Sci 2014; 2:1134-7. |
| [12] | BiadglegneF., Sack U., RodloffAC. Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care, journal of antimicrobial resistance and infection control, http://www.aricjournal.com/content/3/1/31 |
| [13] | Nigus DM, Lingerew WM, Beyene BA, Tamiru AA, Lemma MT, et al. (2014) Prevalence of Multi Drug Resistant Tuberculosis among Presumptive Multi Drug Resistant Tuberculosis Cases in Amhara National Regional State, Ethiopia. J Mycobac Dis 4: 152. |
| [14] | Seyoum B., Demissie M, Worku A, Bekele S, Aseffa A. Prevalence and Drug Resistance Patterns of Mycobacterium tuberculosis among New Smear Positive Pulmonary Tuberculosis Patients in Eastern Ethiopia, Tuberculosis Research and Treatment, http://dx.doi.org/10.1155/2014/753492 |
| [15] | BelloLA,. Shittu MO,. Shittu BT, Oluremi AS,. Akinnuroju ON, Adekola SA. Rifampicinmonoresistant Mycobacterium tuberculosis among the patients visiting chest clinic, state specialist hospital, Akure, Nigeria, International Journal of Research in Medical Sciences, 2014, 2 (3): 1134-1137. |
| [16] | Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLoS Med 8(7): e1001067. doi:10.1371/journal.pmed.1001067. |
| [17] | Zerihun Z., Girmay M., Adane W., Gobena A. Prevalence of Pulmonary Tuberculosis and Associated Risk Factors in Prisons of Gamo Goffa Zone, South Ethiopia: A Cross-Sectional Study. American Journal of Health Research. Vol. 2, No. 5, 2014, pp. 291-297. |
| [18] | Ali H., Zeynudin A., Mekonnen A., Solomon A., Ali S.Smear posetive pulmonary tuberculosis (ptb) prevalence amongst patients at agaro teaching health center, south west Ethiopia, Ethiop J Health Sci, 2012, 22(1):71-76 |
| [19] | Berhe G., Enqueselassie F., Hailu E., Mekonnen W., TekluT. Gebretsadik A., Berhe R., Haile T. Aseffa A. Population-based prevalence survey of tuberculosis in the Tigray region of Ethiopia, BMC Infectious Diseases 2013, 13:448. |
APA Style
Mesfin Worku Hordofa, Teshome Befikadu Adela. (2015). Prevalence of Refampcin Mono Resistant Mycobacterium Tuberculosis Among Suspected Cases Attending at Yirgalem Hospital. Clinical Medicine Research, 4(3), 75-78. https://doi.org/10.11648/j.cmr.20150403.13
ACS Style
Mesfin Worku Hordofa; Teshome Befikadu Adela. Prevalence of Refampcin Mono Resistant Mycobacterium Tuberculosis Among Suspected Cases Attending at Yirgalem Hospital. Clin. Med. Res. 2015, 4(3), 75-78. doi: 10.11648/j.cmr.20150403.13
AMA Style
Mesfin Worku Hordofa, Teshome Befikadu Adela. Prevalence of Refampcin Mono Resistant Mycobacterium Tuberculosis Among Suspected Cases Attending at Yirgalem Hospital. Clin Med Res. 2015;4(3):75-78. doi: 10.11648/j.cmr.20150403.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cmr.20150403.13,
author = {Mesfin Worku Hordofa and Teshome Befikadu Adela},
title = {Prevalence of Refampcin Mono Resistant Mycobacterium Tuberculosis Among Suspected Cases Attending at Yirgalem Hospital},
journal = {Clinical Medicine Research},
volume = {4},
number = {3},
pages = {75-78},
doi = {10.11648/j.cmr.20150403.13},
url = {https://doi.org/10.11648/j.cmr.20150403.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20150403.13},
abstract = {Introduction: Tuberculosis (TB) is a chronic communicable disease caused by Mycobacterium tuberculosis (MTB). M. tuberculosis is a slow- growing bacterium, resistant to most conventional antimicrobial agents partly due to its impermeable cell wall. It may persist in a dormant or latent form, unsusceptible to agents targeting growing bacteria. The Gen Xpert MTB/RIF is an automated molecular test which detects DNA sequences specific for MTB and RIF resistance by polymerase chain reaction with fully integrated sample processing in patients suspected of drug sensitive or multidrug resistant pulmonary tuberculosis. Objective: to determine Rifampicin Mono-Resistance Mycobacterium tuberculosis among patient attending atYirgalem Hospital from August-December, 2014.Method:A cross sectional study was conducted on Rifampicin Mono-Resistance in Mycobacterium tuberculosis among patient attending at Yirgalem Hospital from August-December, 2014,Yirgalem, Ethiopia. Result: A total of 236 participants were included under this study. Among these, males (57.6%) are slightly dominating female. Concerning to treatment history, 177 (75.0%) are new and the rest 59 (25.0%) retreated. Fifty eight (24.6%) of the total subjects were suspected for MDR tuberculosis. Twenty two (9.3%) of the subjects were smear positive. The highest positive finding of rifampcin susceptible Mycobacterium tuberculosis bacilli observed within age group of 16-30.The overall prevalence of pulmonary tuberculosis was 16.5%. From this prevalence, 3.4% was shared by Rifampcin mono-resistant Tuberculosis. Conclusion: Based on our study finding, The overall prevalence of pulmonary tuberculosis was 16.5%. From these, 3.4% was account for Rifampicin Mono-Resistance Mycobacterium tuberculosis among study subject. Most of the affected study subjects were productive age group. Therefore, we recommend that there should be enhanced efforts in detection of MDR tuberculosis in study area to control dissemination of the disease among the community.},
year = {2015}
}
TY - JOUR T1 - Prevalence of Refampcin Mono Resistant Mycobacterium Tuberculosis Among Suspected Cases Attending at Yirgalem Hospital AU - Mesfin Worku Hordofa AU - Teshome Befikadu Adela Y1 - 2015/04/29 PY - 2015 N1 - https://doi.org/10.11648/j.cmr.20150403.13 DO - 10.11648/j.cmr.20150403.13 T2 - Clinical Medicine Research JF - Clinical Medicine Research JO - Clinical Medicine Research SP - 75 EP - 78 PB - Science Publishing Group SN - 2326-9057 UR - https://doi.org/10.11648/j.cmr.20150403.13 AB - Introduction: Tuberculosis (TB) is a chronic communicable disease caused by Mycobacterium tuberculosis (MTB). M. tuberculosis is a slow- growing bacterium, resistant to most conventional antimicrobial agents partly due to its impermeable cell wall. It may persist in a dormant or latent form, unsusceptible to agents targeting growing bacteria. The Gen Xpert MTB/RIF is an automated molecular test which detects DNA sequences specific for MTB and RIF resistance by polymerase chain reaction with fully integrated sample processing in patients suspected of drug sensitive or multidrug resistant pulmonary tuberculosis. Objective: to determine Rifampicin Mono-Resistance Mycobacterium tuberculosis among patient attending atYirgalem Hospital from August-December, 2014.Method:A cross sectional study was conducted on Rifampicin Mono-Resistance in Mycobacterium tuberculosis among patient attending at Yirgalem Hospital from August-December, 2014,Yirgalem, Ethiopia. Result: A total of 236 participants were included under this study. Among these, males (57.6%) are slightly dominating female. Concerning to treatment history, 177 (75.0%) are new and the rest 59 (25.0%) retreated. Fifty eight (24.6%) of the total subjects were suspected for MDR tuberculosis. Twenty two (9.3%) of the subjects were smear positive. The highest positive finding of rifampcin susceptible Mycobacterium tuberculosis bacilli observed within age group of 16-30.The overall prevalence of pulmonary tuberculosis was 16.5%. From this prevalence, 3.4% was shared by Rifampcin mono-resistant Tuberculosis. Conclusion: Based on our study finding, The overall prevalence of pulmonary tuberculosis was 16.5%. From these, 3.4% was account for Rifampicin Mono-Resistance Mycobacterium tuberculosis among study subject. Most of the affected study subjects were productive age group. Therefore, we recommend that there should be enhanced efforts in detection of MDR tuberculosis in study area to control dissemination of the disease among the community. VL - 4 IS - 3 ER -
Information
Email: